Senescent immune cells typically exhibit impaired functionality, upregulation of immune checkpoint molecules such as PD-1, and increased secretion of pro-inflammatory cytokines These features not only compromise anti-tumor immunity but also contribute to immunotherapy resistance, making immune senescence an increasingly important focus in cancer research (14, 15). This evidence concerns the gene PDCD1 and neoplasm.